Full Picture

Article analysis:

The article titled "Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol)" presents a pilot study exploring the efficacy of double ovarian stimulation in women with poor ovarian response undergoing IVF and ICSI treatments. The study found that continuing ovarian stimulation after the first oocyte retrieval from the mild stimulation cycle, during both the follicular and luteal phases, resulted in more opportunities for retrieving oocytes in poor responders. The primary outcome measured was the number of oocytes retrieved, and the secondary measures included fertilization rate, cleavage rate, number of valid embryos, and pregnancy outcomes from cryopreserved embryo transfers.

While the study provides valuable insights into a potential treatment option for women with poor ovarian response, there are several limitations to consider. Firstly, the sample size is small, with only 38 women enrolled according to Bologna criteria. This limits the generalizability of the findings to a larger population. Secondly, there is no control group for comparison purposes. Without a control group receiving standard treatment protocols or placebo treatment, it is challenging to determine whether any observed effects are due to double ovarian stimulation or other factors such as chance or regression to the mean.

Additionally, while the article notes that various treatment protocols have been used to improve ovarian response and pregnancy rates in patients with POR, it does not provide an overview of these protocols or their effectiveness compared to double ovarian stimulation. This omission may lead readers to believe that double ovarian stimulation is currently the most effective treatment option for POR when this may not be true.

Furthermore, while the article notes that mild ovarian stimulation has been proposed as a cost-effective and patient-friendly regimen that optimizes outcomes and risks of treatment for patients with POR, it does not provide information on how much this regimen costs compared to other treatment options. This lack of information may limit patients' ability to make informed decisions about their treatment options based on financial considerations.

Finally, while the article notes that hormone replacement therapy was recommended for endometrial preparation in cases where patients had thin endometria during natural cycles or stimulation cycles, it does not mention any potential risks associated with hormone replacement therapy. This omission may lead readers to believe that hormone replacement therapy is entirely safe when this may not be true.

In conclusion, while the study provides valuable insights into a potential treatment option for women with poor ovarian response undergoing IVF and ICSI treatments, there are several limitations and omissions in its reporting that should be considered when interpreting its findings. Further research with larger sample sizes and control groups is needed before double ovarian stimulation can be recommended as a standard treatment protocol for POR.